Form 4: Cytokinetics Director Edward Kaye Acquires Additional Shares

Cytokinetics Director Edward M. Kaye, MD, acquired 328 shares of common stock at $38.01 per share as part of the director equity program.

Summary

• Edward M. Kaye, MD, a Director of Cytokinetics Inc. (CYTK), acquired 328 shares of common stock.
• The transaction occurred on July 15, 2025, at a price of $38.01 per share.
• This acquisition was part of the Director equity in lieu of cash retainer program.
• Following this transaction, Dr. Kaye beneficially owns 29,986 shares of Cytokinetics common stock.

Sentiment

Score: 7

Explanation: Director acquisition of shares, especially as part of an equity program, generally indicates confidence in the company's future performance and aligns management interests with shareholders.

Positives

• A Director, Edward M. Kaye, MD, increased his stake in Cytokinetics Inc. by acquiring 328 shares.
• The acquisition was part of an equity program, indicating alignment of director interests with shareholders.

Future Outlook

NA

Industry Context

This Form 4 filing reflects an individual insider transaction and does not provide broader industry context or trends.

Corporate Governance

Related Party Transactions

• Acquisition of common stock by Director Edward M. Kaye, MD, as part of the Director equity in lieu of cash retainer program.

Stakeholder Impact

• Shareholders: The acquisition of shares by a director may be viewed as a positive signal of confidence in the company's future performance.

Key Dates

Recommendation

Keywords

Cytokinetics, CYTK, Form 4, Insider Trading, Director, Stock Acquisition, Equity Compensation